Ignite Creation Date:
2025-12-24 @ 6:25 PM
Ignite Modification Date:
2026-01-01 @ 11:55 AM
Study NCT ID:
NCT01171768
Status:
COMPLETED
Last Update Posted:
2011-07-21
First Post:
2010-07-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis
Sponsor:
Samsung Medical Center
Organization:
Study Overview
Official Title:
The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis
Status:
COMPLETED
Status Verified Date:
2011-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: